-
公开(公告)号：US20070026458A1
公开(公告)日：2007-02-01
申请号：US11303754
申请日：2005-12-16
申请人： David Polidori , Scott Siler , Leif Wennerberg , Seth Michelson , Michael Reed
发明人： David Polidori , Scott Siler , Leif Wennerberg , Seth Michelson , Michael Reed
CPC分类号： G01N33/66 , G01N33/6893 , G01N33/723 , G01N2333/62 , G01N2800/042 , G01N2800/52
摘要： The invention encompasses novel biomarkers and methods for assessing insulin resistance in a subject. The novel biomarkers of the invention include various plasma constituent (e.g., insulin, glucose, lactate and/or triglyceride) concentrations. The methods of the invention include measuring various plasma constituent concentrations and calculating a predicted euglycemic hyperinsulinemic clamp glucose infusion rate (GIR) based on the plasma constituent concentrations.
摘要翻译： 本发明包括用于评估受试者中胰岛素抵抗的新型生物标志物和方法。 本发明的新型生物标志物包括各种血浆成分（例如胰岛素，葡萄糖，乳酸和/或甘油三酸酯）浓度。 本发明的方法包括测量各种血浆成分浓度，并基于血浆成分浓度计算预测的正血糖高胰岛素钳位葡萄糖输注速率（GIR）。
-
2.发明申请HORMONE AND DRUG CONCENTRATIONS IN THE PORTAL VEIN AND HEPATIC SINUSOIDS 审中-公开门静脉和静脉麻醉药物中的HORMONE和DRUG浓度公开(公告)号：US20080120039A1
公开(公告)日：2008-05-22
申请号：US11618383
申请日：2006-12-29
申请人： Kevin Hall , David Polidori , Scott Siler
发明人： Kevin Hall , David Polidori , Scott Siler
CPC分类号： G01N33/74 , G06F19/3468 , G16H50/50
摘要： The invention relates to novel methods of informing a medical decision by determining a hormone or drug concentration in a portal vein or hepatic sinusoid of a mammal. The invention also relates to methods of determining hormone or drug concentration in the portal vein or hepatic sinusoids. Further the invention relates to methods of utilizing these concentrations to calculate infusion rates for hormone or drugs in order to achieve a desired portal vein or hepatic sinusoid concentration of such a hormone or drug.
摘要翻译： 本发明涉及通过确定哺乳动物门静脉或肝窦状体中的激素或药物浓度来通知医学决定的新方法。 本发明还涉及确定门静脉或肝窦腔内激素或药物浓度的方法。 此外，本发明涉及利用这些浓度来计算激素或药物的输注速率以达到期望的门静脉或这种激素或药物的肝窦状液浓度的方法。
-
公开(公告)号：US20070032420A1
公开(公告)日：2007-02-08
申请号：US11352455
申请日：2006-02-09
申请人： David Polidori , Scott Siler
发明人： David Polidori , Scott Siler
CPC分类号： A61K31/155 , A61K31/201 , A61K31/444 , A61K38/04 , A61K38/30 , A61K45/06 , A61K2300/00
摘要： In general this invention can be viewed as encompassing novel methods of treating diabetes and insulin resistance. The inventors have made the discovery that increasing secretion of endogenous glucagon-like peptide-1 (GLP-1) in combination with inhibiting the activity of dipeptidyl peptidase I (DPP-IV) can have a significant impact on hyperglycemia and insulin secretion in subjects suffering from diabetes and/or insulin resistance. Further the invention encompasses methods of identifying subjects having elevated secretion of GLP-1, methods of assessing sensitivity to a GLP-1 secretagogue, and methods of treating diabetes in these subjects by administering a GLP-1 secretagogue to alleviate at least one symptom of diabetes.
摘要翻译： 通常，本发明可以被看作是包括治疗糖尿病和胰岛素抵抗的新颖方法。 发明人已经发现内源性胰高血糖素样肽-1（GLP-1）的分泌与抑制二肽基肽酶I（DPP-IV）的活性的组合的增加可以对受试者的高血糖和胰岛素分泌具有显着影响 来自糖尿病和/或胰岛素抵抗。 此外，本发明包括鉴定GLP-1分泌增加的受试者的方法，GLP-1促分泌素的敏感性评估方法以及通过施用GLP-1促分泌素来减轻糖尿病至少一种症状的这些受试者的糖尿病治疗方法 。
-
公开(公告)号：US07353152B2
公开(公告)日：2008-04-01
申请号：US10040373
申请日：2002-01-09
申请人： Paul Brazhnik , Kevin Hall , Dave Polidori , Scott Siler , Jeff Trimmer
发明人： Paul Brazhnik , Kevin Hall , Dave Polidori , Scott Siler , Jeff Trimmer
摘要： The present invention relates generally to a mathematical and computer model of diabetes related disorders (e.g., human type 2 diabetes) within the framework of multiple macronutrient metabolism. The model includes a representation of complex physiological control mechanisms directing, for example, fat metabolism, protein metabolism and/or carbohydrate metabolism. In one embodiment, for example, the model can account for the interconversion between macronutrients, as well as their digestion, absorption, storage, mobilization, and adaptive utilization, as well as the endocrine control of these processes. In this embodiment, the model can simulate, for example, a heterogeneous group of diabetes related disorders, from insulin resistant to severe diabetic, and can predict the likely effects of therapeutic interventions.
摘要翻译： 本发明一般涉及在多种大量营养素代谢的框架内的糖尿病相关病症（例如人2型糖尿病）的数学和计算机模型。 该模型包括指导例如脂肪代谢，蛋白质代谢和/或碳水化合物代谢的复杂生理控制机制的表示。 在一个实施方案中，例如，该模型可以解释大量营养素之间的相互转化以及它们的消化，吸收，储存，动员和适应性利用以及这些过程的内分泌控制。 在该实施方案中，该模型可以模拟例如来自胰岛素抵抗重度糖尿病的异质性糖尿病相关疾病组，并且可以预测治疗干预的可能作用。
-
公开(公告)号：US20100120050A1
公开(公告)日：2010-05-13
申请号：US12616701
申请日：2009-11-11
申请人： Kapil Gadkar , Ananth Kadambi , Cecelia Pearson , Lynn Powell , Scott Siler , Jeff Trimmer
发明人： Kapil Gadkar , Ananth Kadambi , Cecelia Pearson , Lynn Powell , Scott Siler , Jeff Trimmer
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/142
摘要： The invention also provides methods, apparatuses and reagents useful for predicting future atherosclerosis based on expression levels of genes selected from the set of 68 genes with differential expression in response to pioglitazone and rosiglitazone. The invention also discloses reagent sets and biomarkers for predicting progression of atherosclerosis induced by anti-diabetic therapy in a subject. In one particular embodiment the invention provides a method for predict whether a compound will induce atherosclerosis using gene expression data from sub-acute treatments.
摘要翻译： 本发明还提供了可用于预测未来动脉粥样硬化的方法，装置和试剂，其基于选自具有对吡格列酮和罗格列酮的差异表达的68个基因的基因的基因的表达水平。 本发明还公开了用于预测受试者中由抗糖尿病治疗引起的动脉粥样硬化进展的试剂组和生物标志物。 在一个具体实施方案中，本发明提供了使用来自亚急性治疗的基因表达数据来预测化合物是否将诱导动脉粥样硬化的方法。
-
公开(公告)号：US20090070088A1
公开(公告)日：2009-03-12
申请号：US12060142
申请日：2008-03-31
申请人： Paul Brahznik , Kevin Hall , Dave Polidori , Scott Siler , Jeff Trimmer
发明人： Paul Brahznik , Kevin Hall , Dave Polidori , Scott Siler , Jeff Trimmer
IPC分类号： G06G7/60
摘要： The present invention relates generally to a mathematical and computer model of diabetes related disorders (e.g., human type 2 diabetes) within the framework of multiple macronutrient metabolism. The model includes a representation of complex physiological control mechanisms directing, for example, fat metabolism, protein metabolism and/or carbohydrate metabolism. In one embodiment, for example, the model can account for the interconversion between macronutrients, as well as their digestion, absorption, storage, mobilization, and adaptive utilization, as well as the endocrine control of these processes. In this embodiment, the model can simulate, for example, a heterogeneous group of diabetes related disorders, from insulin resistant to severe diabetic, and can predict the likely effects of therapeutic interventions.
摘要翻译： 本发明一般涉及在多种大量营养素代谢的框架内的糖尿病相关病症（例如人2型糖尿病）的数学和计算机模型。 该模型包括指导例如脂肪代谢，蛋白质代谢和/或碳水化合物代谢的复杂生理控制机制的表示。 在一个实施方案中，例如，该模型可以解释大量营养素之间的相互转化以及它们的消化，吸收，储存，动员和适应性利用以及这些过程的内分泌控制。 在该实施方案中，该模型可以模拟例如来自胰岛素抵抗重度糖尿病的异质性糖尿病相关疾病组，并且可以预测治疗干预的可能作用。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.032 秒)